Global Bio-chem Technology Group Co. Ltd / ADR
GBCMYDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Fezolinetant
Hot Flashes
Gilteritinib
Acute Myeloid Leukemia (AML)
Enzalutamide
HER2 Amplified
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fezolinetant | Phase 3 | Hot Flashes | - | - |
Gilteritinib | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
Enzalutamide | Phase 2 | HER2 Amplified | - | - |
Frequently asked questions
What is in Global Bio-chem Technology Group Co. Ltd / ADR's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Global Bio-chem Technology Group Co. Ltd / ADR's (GBCMY) pipeline across Phase 3, Phase 2. Its lead program is Fezolinetant (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Global Bio-chem Technology Group Co. Ltd / ADR's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Global Bio-chem Technology Group Co. Ltd / ADR (GBCMY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GBCMY biotech catalysts?→
Add GBCMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Global Bio-chem Technology Group Co. Ltd / ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.